Name

The Precision Peptide Company

Legal name

Concord Health Products Inc.

Website

https://precisionpeptidecompany.com

Company type

Public

Operating status

Operating

Ownership category

akta.pro rank

Product category

Peptide Wellness Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD)

Keywords

• Peptide therapy protocols
• Transdermal drug delivery
• Compounded pharmaceuticals
• Telehealth wellness services
• Longevity medicine

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Marketing or Sales, Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

1. Subscription Protocol Fees: Monthly subscription fees for physician-guided peptide protocols. Two primary protocols offered: Tirzepatide at $349/month for weight management and NAD+ at $159/month for cellular energy and longevity. Recurring monthly billing with free shipping included.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

The Precision Peptide Company provides physician-guided peptide therapy protocols through a direct-to-consumer telehealth platform. Its current offerings include monthly subscription protocols for Tirzepatide (weight management at $349/month) and NAD+ (longevity/cellular energy at $159/month), dispensed through FDA-regulated 503A compounding pharmacies with licensed provider review across all 50 U.S. states. The company is also developing a needle-free transdermal peptide patch platform (BPC-157 patch as lead candidate and an Immune Defense Patch with Thymosin Alpha-1) under its wholly-owned Amino Innovations subsidiary.

Product overview

The Precision Peptide Company operates as a peptide wellness company offering physician-guided peptide therapy protocols through a telehealth platform. The core product portfolio consists of two injectable peptide protocols (Tirzepatide at $349/month for weight loss and NAD+ at $159/month for longevity/cellular energy), both fulfilled through FDA-regulated 503A compounding pharmacies with licensed provider review across all 50 U.S. states. The company is also developing a needle-free transdermal peptide delivery platform under the Amino Innovations sub-brand, featuring the BPC-157 Transdermal Patch (lead product candidate achieving 95.5% purity) and an Immune Defense Patch with Thymosin Alpha-1. All products require physician prescription and are manufactured in the United States.

Differentiator

Problem solved

Functional benefit

Brands

• Amino Innovations: Wholly-owned subsidiary brand operating the company's transdermal peptide platform and needle-free patch delivery technology including BPC-157 transdermal patch and Immune Defense Patch with Thymosin Alpha-1.

Products and services

• Tirzepatide Weight Loss Protocol

Quantifiable outcome

• 95.5% chromatographic purity confirmed by independent testing, exceeding ≥95% industry benchmark
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• U.S.-Based Telehealth and Prescription Infrastructure PartnercoreChannel Partner/ Reseller/ Distributor · 9 June 2026Agreement to support compliant prescribing, fulfillment, and delivery of peptide products across all 50 U.S. states. Builds on previously announced 503A compounding agreement. Connected to licensed provider networks trusted by 100+ telehealth brands. Designed to align with U.S. legal, HIPAA, and pharmacy regulations. Established ahead of FDA's PCAC review of BPC-157 scheduled for July 23, 2026.
• Emerging Markets Consulting, LLCminorGTM or Marketing Partner · 8 June 2026Investor relations services agreement extended for additional six months starting June 8, 2026. Deal valued at USD $150,000 for continued IR services.
• Uniloop LLCcoreTechnology or Integration · 28 May 2026Telehealth platform partner handling PHI for telehealth intake, provider review, prescribing, and related clinical workflows. Licensed provider review of patient information and prescription decisions. Supports 50-state coverage and HIPAA compliance.
• Miraxis LabsminorOthers · 19 May 2026Independent laboratory testing confirming BPC-157 transdermal patch achieved 95.5% chromatographic purity and 2.02mg quantified dose per patch using UHPLC-DAD methodology. Results certified by two PhD scientists. Positions company as quality-first operator in market where independent verification is not standard practice.
• MMA.INC (Mixed Martial Arts Group Limited)coreGTM or Marketing Partner · 8 May 2026Exclusive strategic marketing partnership granting Precision Peptide marketing rights across MMA.INC's global combat sports ecosystem comprising 5M+ social followers, 530,000 user profiles, 75,000+ active students, and 800+ verified gyms across 16 countries. Net revenue shared 50/50 in Year 1, transitioning to 75/25 in favor of Precision. Products manufactured in U.S. and FDA-compliant. Advisory roster includes Conor McGregor, Donald Trump Jr., John Kavanagh, and Laura Sanko.
• Drug Development and Innovation Centre at University of AlbertaminorStrategic or Co-development Partner · 7 May 2026Research services agreement supporting development of needle-free BPC-157 transdermal patch. Testing focused on absorption, bioavailability, and stability for scalable consumer delivery. Part of Amino Innovations platform development.
• Raw CreationminorGTM or Marketing Partner · 20 April 2026UK-headquartered creative agency providing social media management, creative content, editorial, and paid advertising services. Initial six-month term (April 20 to October 20, 2026) valued at CAD$85,500 (CAD$9,000 setup fee plus CAD$76,500 prepaid retainer). Converts to rolling monthly retainer of CAD$15,000 after initial term, subject to CSE approval.
• Think Ink Marketing Data and Email ServicesminorGTM or Marketing Partner · 15 April 2026Public relations services contract valued at $250,000 for 12-month term. Combined with $65,000 consulting agreement with Ouimet Consulting Inc. (1-month term). Total $315,000 in service agreements, subject to CSE approval. Designed to increase public awareness of the company.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Marek Health: Telehealth platform specializing in hormone optimization and peptide therapy with clinician-guided protocols. Directly comparable peptide therapy positioning, telehealth prescribing workflow, and performance/wellness consumer targeting.
• Ro: Telehealth platform operating Roman (men's health), Rory (women's health), and Ro Body (weight management including compounded GLP-1s). Directly comparable D2C telehealth subscription model, physician-reviewed protocols, and pharmacy fulfillment across all 50 states.
• Fountain Health (formerly Fountain TRT): Telehealth clinic offering hormone replacement therapy and peptide protocols with licensed provider review and home delivery. Overlapping business model in physician-guided peptide therapy with a focus on longevity and performance optimization.
• LifeMD: Public telehealth company (LFMD) providing direct-to-patient virtual care including weight management and hormone therapy. Comparable subscription model and clinical infrastructure with overlapping consumer target and prescription-based fulfillment through partner pharmacies.
• Wonder Medicine: Telehealth provider specializing in peptide therapy, hormone optimization, and weight management with physician-supervised protocols. Closely comparable peptide-therapy-only positioning and direct-to-consumer subscription fulfillment.
• Hims & Hers Health: Public telehealth wellness platform (HIMS) offering direct-to-consumer prescription products including weight management via compounded GLP-1s. Closely comparable business model: online health assessment, licensed provider review, subscription fulfillment, with category overlap on Tirzepatide weight loss.

Broad incumbents

• Thorne HealthTech: Public wellness and supplement company offering science-backed nutraceuticals, including peptide-related products, through direct-to-consumer and practitioner channels. Comparable premium positioning in the science-driven wellness consumer segment, though broader portfolio without a telehealth/prescription model.

Emerging players

• Revive Wellness: Specialty clinic and telehealth provider of peptide therapy, NAD+, and hormone optimization with physician-supervised protocols. Overlapping peptide wellness focus with a narrower geographic footprint and emerging brand recognition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Precision Peptide Company